<DOC>
	<DOCNO>NCT00734344</DOCNO>
	<brief_summary>This single-site , investigator-initiated , open-label , randomized/controlled clinical trial compare viral load response plasma ( , subset subject , gastrointestinal lymphoid tissue reservoir ) subject acute/early HIV-1 infection treat 12 week raltegravir-based versus efavirenz-based ART ( combine tenofovir/emtricitabine ) . Subjects receive self-limited course therapy rather commitment life-long HAART , experimental approach variety clinical protocol United States Europe . Subjects complete 12 week course therapy , meet treatment-response safety criterion undergo similarly intensive period virology immunology monitor compare time dynamic observe virologic rebound follow treatment intervention .</brief_summary>
	<brief_title>Pilot Study Raltegravir/Truvada Versus Efavirenz/Truvada Adults With Acute IV-1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Subjects 19 year age old meet NIH Acute Infection Early Disease Research Program ( AIEDRP ) definition acute early HIV1 infection . Briefly , acute HIV1 infection define &gt; 5000 copy per milliliter HIV RNA one follow document within 7 day period initial positive PCRbased assay : 1 ) negative HIV1 EIA 2 ) positive EIA negative indeterminant HIV1 Western Blot test ( interpret base current CDC guideline ) . For purpose protocol , early HIV1 infection define detectable HIV RNA PCRbased assay , positive HIV EIA , positive HIV1 Western blot , one following : 1 ) document negative HIV EIA precede 6 month 2 ) HIV detuned EIA standardize optical density measurement ( defined sample OD negative control OD/ positive control OD ) &lt; 1.0 within 14 day positive HIV EIA ( consistent acute infection occur past 120 day ) . Lack consistent evidence seroconversion document appropriate antibody test persistent HIV infection screen early followup period . Prior receipt antiretroviral therapy . Serum creatinine &gt; 2.0 x upper limit normal calculated creatinine clearance time screen &lt; 30 mL/min ( 0.85X value female ) . Alkaline phosphatase &gt; 5 x upper limit normal . AST ( SGOT ) ALT ( SGPT ) &gt; 5 x upper limit normal . Repeat laboratory screen test allow test result unexpected base document prior laboratory result monitor decline trend may relate primary retroviral syndrome . Have severe medical illness investigator feel interfere ability take therapy result make therapy risky subject . This include active tuberculosis treatment , severe liver disease due alcoholism viral hepatitis , unstable cardiovascular cerebrovascular disease . Have significant psychiatric illness ongoing substance abuse , opinion investigator , would compromise ability subject provide adequate inform consent adhere study procedure safely consistently . Women pregnant actively breastfeeding time screen . Men woman actively attempt become pregnant , unable unwilling institute adequate birth control measure entire course treatment protocol .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>